89 related articles for article (PubMed ID: 16503496)
1. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity.
Chen X; Zeng Y; Li G; Larmonier N; Graner MW; Katsanis E
Biol Blood Marrow Transplant; 2006 Mar; 12(3):275-83. PubMed ID: 16503496
[TBL] [Abstract][Full Text] [Related]
2. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
Zeng Y; Graner MW; Thompson S; Marron M; Katsanis E
Blood; 2005 Mar; 105(5):2016-22. PubMed ID: 15374884
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers.
Graner MW; Zeng Y; Feng H; Katsanis E
Cancer Immunol Immunother; 2003 Apr; 52(4):226-34. PubMed ID: 12669247
[TBL] [Abstract][Full Text] [Related]
4. Chaperone-rich cell lysates, immune activation and tumor vaccination.
Zeng Y; Graner MW; Katsanis E
Cancer Immunol Immunother; 2006 Mar; 55(3):329-38. PubMed ID: 15887013
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.
Ling X; Wang Y; Dietrich MF; Andreeff M; Arlinghaus RB
Oncogene; 2006 Jul; 25(32):4483-90. PubMed ID: 16547503
[TBL] [Abstract][Full Text] [Related]
6. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic MHC gene transfer enhances an effective antitumor immunity in the early period of autologous hematopoietic stem cell transplantation.
Kobayashi A; Hara H; Ohashi M; Nishimoto T; Yoshida K; Ohkohchi N; Yoshida T; Aoki K
Clin Cancer Res; 2007 Dec; 13(24):7469-79. PubMed ID: 18094431
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination.
Zeng Y; Chen X; Larmonier N; Larmonier C; Li G; Sepassi M; Marron M; Andreansky S; Katsanis E
Int J Cancer; 2006 Dec; 119(11):2624-31. PubMed ID: 16989012
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.
Janikashvili N; LaCasse CJ; Larmonier C; Trad M; Herrell A; Bustamante S; Bonnotte B; Har-Noy M; Larmonier N; Katsanis E
Blood; 2011 Feb; 117(5):1555-64. PubMed ID: 21123824
[TBL] [Abstract][Full Text] [Related]
10. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
11. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma.
Graner M; Raymond A; Romney D; He L; Whitesell L; Katsanis E
Clin Cancer Res; 2000 Mar; 6(3):909-15. PubMed ID: 10741715
[TBL] [Abstract][Full Text] [Related]
12. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity.
Zeng Y; Feng H; Graner MW; Katsanis E
Blood; 2003 Jun; 101(11):4485-91. PubMed ID: 12576309
[TBL] [Abstract][Full Text] [Related]
13. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.
Rossi GR; Mautino MR; Awwad DZ; Husske K; Lejukole H; Koenigsfeld M; Ramsey WJ; Vahanian N; Link CJ
J Immunother; 2008; 31(6):545-54. PubMed ID: 18528300
[TBL] [Abstract][Full Text] [Related]
16. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.
Kislin KL; Marron MT; Li G; Graner MW; Katsanis E
FASEB J; 2007 Jul; 21(9):2173-84. PubMed ID: 17327358
[TBL] [Abstract][Full Text] [Related]
17. Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression.
Larmonier N; Cantrell J; Lacasse C; Li G; Janikashvili N; Situ E; Sepassi M; Andreansky S; Katsanis E
J Leukoc Biol; 2008 Apr; 83(4):1049-59. PubMed ID: 18174364
[TBL] [Abstract][Full Text] [Related]
18. Induction of leukemia-specific antibodies by immunotherapy with leukemia-cell-derived heat shock protein 70.
Jimbo J; Sato K; Hosoki T; Shindo M; Ikuta K; Torimoto Y; Kohgo Y
Cancer Sci; 2008 Jul; 99(7):1427-34. PubMed ID: 18452562
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.
U'Ren L; Kedl R; Dow S
Cancer Gene Ther; 2006 Nov; 13(11):1033-44. PubMed ID: 16841080
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantation.
Hamaguchi M; Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Teshima T; Harada M; Yoshikai Y; Naito S
Cancer Sci; 2009 Jan; 100(1):138-43. PubMed ID: 19037994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]